The LAM Foundation Mission and History
The LAM Foundation urgently seeks safe and effective treatments, and ultimately a cure, for lymphangioleiomyomatosis (LAM) through advocacy and the funding of promising research. We are dedicated to serving the scientific, medical and patient communities by offering information, resources and a worldwide network of hope and support.
The LAM Foundation is the global leader in the fight against Lymphangioleiomyomatosis (LAM). The Foundation began in 1995 as a grass roots effort and has evolved into an organization that is described by the National Heart, Lung, and Blood Institute (NHLBI) as "a model for voluntary health agencies." Headquartered in Cincinnati, Ohio, the Foundation embodies all of the elements required to move LAM research from the laboratory to the clinic. The Foundation embraces women with LAM and their families, provides support and education, engages doctors and scientists, and raises funds for the study of LAM. With the funding of promising research as our central mission, the Foundation has elevated LAM from the ranks of rare and forgotten diseases into the minds of many experts in pulmonary medicine. The LAM Foundation funded the first LAM research that resulted in the fundamental understanding of the genetic cause of LAM and the first ever LAM treatment trial. It is amazing how far LAM research has come in such a short period of time, thanks especially to the many researchers who have helped to make this disease a research priority. LAM and Tuberous Sclerosis researchers have identified a wealth of potential molecular targets and experimental therapies that may be appropriate for testing in clinical trials. Many of these drugs are FDA-approved or in development for other indications.
The LAM Foundation is committed to serving the unique needs of women with LAM. In fulfilling our mission, we are guided by the following principles:
Click here to see Milestones in LAM.